Infliximab in the treatment of Crohn's disease

• DOI: 10.2147/tcrm.2007.3.2.301
• Publication Date: 2007-05-27T17:05:01Z
• Authors: Gilberto Poggioli; Silvio Laureti; Massimo Campieri; Filippo Pierangeli; Paolo Gionchetti; Federica Ugolini; Lorenzo Gentilini; Piero Bazzi; Fernando Rizzello; Maurizio Coscia
• Keywords: 03 medical and health sciences; 0302 clinical medicine; infliximab, Crohn’s disease, perianal fistulas, local injection; 3. Good health

The recent introduction of infliximab, a chimeric monoclonal antibody against tumor necrosis factor-α, has greatly modified the treatment Crohn's disease (CD).Data from literature show encouraging results after intravenous infusion both for closure intestinal or perianal fistulas and induction maintenance remission in patients with moderate to severe unresponsive other treatments.However, some contraindications such as fibrostenosing CD sepsis have been identified.In addition, data on long-term outcomes safety is still limited.Our initial experience showed that selected cases local injection infliximab effective complex offering possibility using even small bowel obstructing minimal systemic effects.This paper analyzes state use CD.